GlassScriptPhysician profile
Aris P Delianides
NPI 1902807449
$4,112.07
in general payments reported to CMS, 2019-2025
38 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $503 · 2021: $435 · 2022: $407 · 2023: $935 · 2024: $1,180 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,486 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,485.95 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $938.87 | 2021-2025 | Qulipta, Ubrelvy |
| Alcon Vision LLC | $703.69 | 2020-2025 | Ngenuity, Clareon, Ora System Verifeye |
| Alexion Pharmaceuticals, INC. | $411.94 | 2019-2025 | Ultomiris, Soliris |
| Teva Pharmaceuticals USA, INC. | $254.43 | 2021-2025 | Ajovy, Austedo Xr |
| Ucb, INC. | $186.37 | 2019-2023 | Briviact |
| Lilly USA, LLC | $173.10 | 2020-2025 | Emgality, Reyvow |
| Amgen INC. | $139.22 | 2019-2023 | Aimovig |
| Ocular Therapeutix, INC. | $130.36 | 2020 | |
| Emd Serono, INC. | $126.82 | 2020-2024 | |
| Sight Sciences, INC. | $90.85 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $88.40 | 2022 | |
| Currax Pharmaceuticals LLC | $73.03 | 2020-2021 | |
| Rayner Intraocular Lenses Limited | $65.49 | 2022-2024 | Rayone Aspheric, Rayone Spheric, Omidria |
| Genentech USA, INC. | $58.92 | 2020-2023 | Enspryng |
| Rxsight INC | $55.72 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $50.75 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $50.72 | 2021 | |
| Mallinckrodt Hospital Products INC. | $49.87 | 2020-2023 | Acthar |
| Horizon Therapeutics Plc | $42.87 | 2020-2022 | |
| Upsher-Smith Laboratories LLC | $40.89 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $36.21 | 2021 | |
| Lundbeck LLC | $31.25 | 2023 | Vyepti |
| Bayer Healthcare Pharmaceuticals INC. | $28.08 | 2019-2021 | |
| Pfizer INC. | $26.04 | 2023 | |
| Sk Life Science, INC. | $21.62 | 2020 | |
| Sanofi-Aventis U.S. LLC | $21.24 | 2020 | |
| Genzyme Corporation | $20.75 | 2022 | |
| Banner Life Sciences, LLC | $20.32 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $20.26 | 2023 | Acuvue |
| Biogen, INC. | $19.75 | 2023 | Vumerity |
| Merz Pharmaceuticals, LLC | $19.41 | 2024 | Ampyra, Xeomin |
| Assertio Therapeutics, INC. | $19.32 | 2019 | |
| Mallinckrodt Enterprises LLC | $17.44 | 2019 | |
| Corium, LLC | $17.12 | 2023 | Adlarity |
| Spark Therapeutics, INC. | $17.03 | 2021 | |
| Avanir Pharmaceuticals, INC. | $16.82 | 2021 | |
| Celgene Corporation | $14.92 | 2021 | |
| Coopervision INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aris Delianides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.